Felypressin

DB00093InvestigationalProtein Based Therapies

A synthetic nonapeptide comprising cysteinyl, phenylalanyl, phenylalanyl, glutaminyl, asparaginyl, cysteinyl, prolyl, lysyl, and glycinamide residues in sequence, with a disulfide bridge joining the two cysteine residues. Its antidiuretic effects are... Its antidiuretic effects are less than those of vasopressin.

Mechanism: Felypressin binds to the vasopressin receptor V1a. This causes contraction of the smooth muscle in the vascular bed, especially capillaries, small arterioles and venules.
Curator reviewed
Primary indication: For use as an alternative to adrenaline as a localising agent, provided that local ischaemia is not essential.Curator reviewed
Also known as: PLV-2

Resolves to

Compound

UNII17N2918V6GCAS56-59-7ChEMBLCHEMBL3185126ChEBI60564PubChem14257662

Clinical / RWD

RxNorm4319PharmGKBPA164744374

Targets

P37288AVPR1A

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

3Marketed productsAcross 2 countries and 3 labellers

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Felypressin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account